116 related articles for article (PubMed ID: 18781300)
21. Allergy in Cancer Care: Antineoplastic Therapy-Induced Hypersensitivity Reactions.
Galateanu B; Pușcașu AI; Tircol SA; Tanase BC; Hudita A; Negrei C; Burcea-Dragomiroiu GT; Negreanu L; Vacaroiu IA; Ginghină O
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835299
[TBL] [Abstract][Full Text] [Related]
22. Successful rechallenge with cetuximab after an infusion related reaction to panitumumab in a patient with locally advanced rectal cancer.
Yokokawa H; Kono T; Shidei H; Oyama K; Ito Y; Imaizumi R; Miyano Y; Shiozawa S; Yoshimatsu K
Int Cancer Conf J; 2021 Jan; 10(1):87-90. PubMed ID: 33489709
[TBL] [Abstract][Full Text] [Related]
23. Biological agents in gastrointestinal cancers: adverse effects and their management.
Arora N; Gupta A; Singh PP
J Gastrointest Oncol; 2017 Jun; 8(3):485-498. PubMed ID: 28736636
[TBL] [Abstract][Full Text] [Related]
24. Patient considerations in metastatic colorectal cancer - role of panitumumab.
Rogers JE
Onco Targets Ther; 2017; 10():2033-2044. PubMed ID: 28435294
[TBL] [Abstract][Full Text] [Related]
25. Panitumumab in Japanese patients with unresectable colorectal cancer: a post-marketing surveillance study of 3085 patients.
Boku N; Sugihara K; Kitagawa Y; Hatake K; Gemma A; Yamazaki N; Muro K; Hamaguchi T; Yoshino T; Yana I; Ueno H; Ohtsu A
Jpn J Clin Oncol; 2014 Mar; 44(3):214-23. PubMed ID: 24526771
[TBL] [Abstract][Full Text] [Related]
26. Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens: Clinical outcome and biomarkers of efficacy.
Pietrantonio F; Perrone F; Biondani P; Maggi C; Lampis A; Bertan C; Venturini F; Tondulli L; Ferrari D; Ricci V; Villa F; Barone G; Bianco N; Ghidini A; Bossi I; Fanetti G; Di Bartolomeo M; de Braud F
Cancer Biol Ther; 2013 Dec; 14(12):1098-103. PubMed ID: 24025413
[TBL] [Abstract][Full Text] [Related]
27. Molecular targeted approaches for treatment of pancreatic cancer.
Huang ZQ; Saluja AK; Dudeja V; Vickers SM; Buchsbaum DJ
Curr Pharm Des; 2011; 17(21):2221-38. PubMed ID: 21777178
[TBL] [Abstract][Full Text] [Related]
28. Different patterns of toxicity after sequential administration of two anti-EGFR monoclonal antibodies.
López-Gómez M; Gómez-Raposo C; Sereno M; Zambrana F; Casado E
Clin Transl Oncol; 2010 Nov; 12(11):775-7. PubMed ID: 20974572
[TBL] [Abstract][Full Text] [Related]
29. Development trends for human monoclonal antibody therapeutics.
Nelson AL; Dhimolea E; Reichert JM
Nat Rev Drug Discov; 2010 Oct; 9(10):767-74. PubMed ID: 20811384
[TBL] [Abstract][Full Text] [Related]
30. Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer.
Fakih M; Vincent M
Curr Oncol; 2010 Jul; 17 Suppl 1(Suppl 1):S18-30. PubMed ID: 20680104
[TBL] [Abstract][Full Text] [Related]
31. Current status of treatment of metastatic colorectal cancer with special reference to cetuximab and elderly patients.
Pfeiffer P; Qvortrup C; Bjerregaard JK
Onco Targets Ther; 2009 Feb; 2():17-27. PubMed ID: 20616891
[TBL] [Abstract][Full Text] [Related]
32. Colon cancer and the elderly: from screening to treatment in management of GI disease in the elderly.
Holt PR; Kozuch P; Mewar S
Best Pract Res Clin Gastroenterol; 2009; 23(6):889-907. PubMed ID: 19942166
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of panitumumab following cetuximab: retrospective review of the Memorial Sloan-Kettering experience.
Power DG; Shah MA; Asmis TR; Garcia JJ; Kemeny NE
Invest New Drugs; 2010 Jun; 28(3):353-60. PubMed ID: 19468688
[TBL] [Abstract][Full Text] [Related]
34. Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers.
Harandi A; Zaidi AS; Stocker AM; Laber DA
J Oncol; 2009; 2009():567486. PubMed ID: 19424511
[TBL] [Abstract][Full Text] [Related]
35. Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature.
Saif MW; Peccerillo J; Potter V
Cancer Chemother Pharmacol; 2009 May; 63(6):1017-22. PubMed ID: 18781300
[TBL] [Abstract][Full Text] [Related]
36. Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer.
Saif MW; Syrigos KI; Hotchkiss S; Shanley J; Grasso J; Ferencz TM; Syrigos K; Shah MM
Cancer Chemother Pharmacol; 2009 Dec; 65(1):107-12. PubMed ID: 19415280
[TBL] [Abstract][Full Text] [Related]
37. Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: a case report.
Heun J; Holen K
Clin Colorectal Cancer; 2007 May; 6(7):529-31. PubMed ID: 17553202
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of panitumumab therapy after progression with cetuximab: experience at two institutions.
Saif MW; Kaley K; Chu E; Copur MS
Clin Colorectal Cancer; 2010 Dec; 9(5):315-8. PubMed ID: 21208847
[TBL] [Abstract][Full Text] [Related]
39. Anti-EGFR monoclonal antibodies for treatment of colorectal cancers: development of cetuximab and panitumumab.
You B; Chen EX
J Clin Pharmacol; 2012 Feb; 52(2):128-55. PubMed ID: 21427284
[TBL] [Abstract][Full Text] [Related]
40. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
Jean GW; Shah SR
Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
